Social Anxiety Support

Drew · 11-12-2008, 11:03 AM

Improving Outcomes in Pharmacotherapy of Social Phobia

Massachusetts General Hospital

Study Contact: call 1-866-44-WORRY or send email to anxietystudy@partners.org

Description: This study will compare the usefulness of three different medication strategies for treating individuals with social anxiety disorder who have not responded well to an established treatment (i.e., the medication sertraline, also known as ZoloftÒ). Each of these 3 medication strategies involve taking a medication that is currently marketed for anxiety and approved by the U.S. Food and Drug Administration (FDA) for sale for the treatment of anxiety. The study is a two phase, 23-week research study in which subjects who remain symptomatic at the end of one phase enter into the next. In Phase I, all subjects receive sertraline (ZoloftÒ) for 10 weeks. Subjects who remain symptomatic will enter Phase II, in which subjects will be randomly assigned (there will be a one-in-three chance of being assigned to each group) to either keep taking sertraline, switch to taking sertraline and clonazepam, or switch to taking only venlafaxine extended-release for the remaining 12 weeks of the study. At the end of the study, you will enter follow-up care with the study doctor.

Inclusion Criteria: Patients age 18 or older with a primary diagnosis of generalized social anxiety disorder. Patients with a history of schizophrenia, psychotic disorders, bipolar disorder, mental disorder due to a medical condition or substance, obsessive-compulsive disorder, or post-traumatic stress disorder are excluded. In addition, patients with severe and/or uncontrolled medical problems, and patients taking other psychotrophic medications are excluded.

11-12-2008, 11:03 AM	#1 (permalink)
Drew Status: Administrator Join Date: Jan 2006 Location: Seattle, WA Gender: Male Posts: 1,381	Improving Outcomes in Pharmacotherapy of Social Phobia (Boston, Massachusetts) Improving Outcomes in Pharmacotherapy of Social Phobia Massachusetts General Hospital Study Contact: call 1-866-44-WORRY or send email to anxietystudy@partners.org Description: This study will compare the usefulness of three different medication strategies for treating individuals with social anxiety disorder who have not responded well to an established treatment (i.e., the medication sertraline, also known as ZoloftÒ). Each of these 3 medication strategies involve taking a medication that is currently marketed for anxiety and approved by the U.S. Food and Drug Administration (FDA) for sale for the treatment of anxiety. The study is a two phase, 23-week research study in which subjects who remain symptomatic at the end of one phase enter into the next. In Phase I, all subjects receive sertraline (ZoloftÒ) for 10 weeks. Subjects who remain symptomatic will enter Phase II, in which subjects will be randomly assigned (there will be a one-in-three chance of being assigned to each group) to either keep taking sertraline, switch to taking sertraline and clonazepam, or switch to taking only venlafaxine extended-release for the remaining 12 weeks of the study. At the end of the study, you will enter follow-up care with the study doctor. Inclusion Criteria: Patients age 18 or older with a primary diagnosis of generalized social anxiety disorder. Patients with a history of schizophrenia, psychotic disorders, bipolar disorder, mental disorder due to a medical condition or substance, obsessive-compulsive disorder, or post-traumatic stress disorder are excluded. In addition, patients with severe and/or uncontrolled medical problems, and patients taking other psychotrophic medications are excluded.